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ABSTRACT In2009,anovelH1N1inﬂuenzaAvirus(2009pH1N1)emergedandcausedapandemic.Ahumanmonoclonalanti-
body(hMAb;EM4C04),highlyspeciﬁcforthe2009pH1N1virushemagglutinin(HA),wasisolatedfromaseverelyill2009
pH1N1virus-infectedpatient.WepostulatedthatunderimmunepressurewithEM4C04,the2009pH1N1viruswouldundergo
antigenicdriftandmutateatsitesthatwouldidentifytheantibodybindingsite.Todoso,weinfectedMDCKcellsinthepres-
enceofEM4C04andgenerated11escapemutants,displaying7distinctaminoacidsubstitutionsintheHA.Sixsubstitutions
greatlyreducedMAbbinding(K123N,D131E,K133T,G134S,K157N,andG158E).Residues131,133,and134arecontiguous
withresidues157and158intheglobulardomainstructureandcontributetoanovelpH1N1antibodyepitope.Onemutation
nearthereceptorbindingsite,S186P,increasedthebindingafﬁnityoftheHAtothereceptor.186Pand131Earepresentinthe
highlyvirulent1918virusHAandwererecentlyidentiﬁedasvirulencedeterminantsinamouse-passagedpH1N1virus.We
foundthatpH1N1escapevariantsexpressingthesesubstitutionsenhancedreplicationandlethalityinmicecomparedtowild-
type2009pH1N1virus.Theincreasedvirulenceoftheseviruseswasassociatedwithanincreasedafﬁnityfor 2,3sialicacidre-
ceptors.OurstudydemonstratesthatantibodypressurebyanhMAbtargetinganovelepitopeintheSaregionof2009pH1N1
HAisabletoinadvertentlydrivethedevelopmentofamorevirulentviruswithalteredreceptorbindingproperties.Thisbroad-
ensourunderstandingofantigenicdrift.
IMPORTANCE Inﬂuenzavirusesaccumulateaminoacidsubstitutionstoevadetheantibodyresponseinaprocessknownasanti-
genicdrift,makingitnecessarytovaccinateagainstinﬂuenzaannually.Mappinghumanmonoclonalantibody(hMAb)epitopes
isanecessarysteptowardsunderstandingantigenicdriftinhumans.WedeﬁnedthespeciﬁcityofanhMAbthatspeciﬁcallytar-
getedthe2009pH1N1virusanddescribeanovelepitope.Inaddition,weidentiﬁedapreviouslyunappreciatedpotentialforan-
tibody escape to enhance the pathogenicity of a virus. The escape mutation that we identiﬁed with in vitro immune pressure was
independently reported by other investigators using in vivo selection in nonimmune mice. Although in vitro generation of es-
capemutantsisunlikelytorecapitulateantigenicdriftinitsentirety,thedatademonstratethatpressurebyahumanmonoclo-
nalantibodytargetinganovelepitopeinthehemagglutininofthe2009pandemicH1N1viruscaninadvertentlydrivethedevel-
opmentofescapemutants,ofwhichasubsethaveincreasedvirulenceandalteredreceptorbindingproperties.
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H
emagglutinin (HA) and neuraminidase (NA), the major en-
velopeglycoproteinsofinﬂuenzaviruses,aretheprimarytar-
getsoftheprotectiveimmuneresponsetoinﬂuenzaAviruses(1).
Protectionagainstinﬂuenzavirusinfectionismostefﬁcientlyme-
diated by neutralizing antibodies (Abs), whose induction likely
provides the basis for the protective efﬁcacy of licensed vaccines
(2-4).WhileantibodiesagainstHAorNAcanimpairviralspread,
only anti-HA antibodies efﬁciently neutralize inﬂuenza viruses in
vitro and in vivo by blocking HA-mediated virus attachment and
cell entry, making HA the critical target of the antibody response
(5-8).
As inﬂuenza viruses evolve in humans, they undergo gradual
changes in the HA and NA proteins in a continuous process
known as “antigenic drift.” During antigenic drift, inﬂuenza vi-
ruses accumulate amino acid substitutions in the HA globular
domain that select for resistance to neutralization by HA-speciﬁc
antibodies. This facilitates the continued circulation of inﬂuenza
viruses in the human population and their ability to cause annual
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globulardomain(Sa,Sb,Ca1,Ca2,andCb)thatarerecognizedby
neutralizing murine monoclonal antibodies (MAbs) (9-11).
However, human MAbs (hMAbs) that bind to the inﬂuenza virus
HAinteractwith2ormoreofthesesitesaswellasregionsbetween
them. Characterization of the antigenic sites is critical for reveal-
ing the mechanisms that drive inﬂuenza virus evolution.
Inadditiontoantigenicdrift,inﬂuenzaviruseswithanovelHA
with or without an accompanying novel NA gene from an animal
sourceareperiodicallyintroducedintothehumanpopulationina
process known as “antigenic shift” (12). This can be a conse-
quence of genetic reassortment among inﬂuenza viruses or by
directintroductionofananimalinﬂuenzavirusintohumans(12-
14). Antigenic shift can result in the emergence and pandemic
spread of novel inﬂuenza viruses in an immunologically naive
human population (12-14). The 2009 pandemic H1N1 virus is a
reassortant swine inﬂuenza virus with genes derived from North
AmericanH3N2andH1N2swinevirusesandEurasianavian-like
swinevirusesandquicklyestablisheditselfasthedominantH1N1
lineagecirculatinginhumans(13).Likepreviouspandemicinﬂu-
enzaviruses,itisexpectedthatthe2009pH1N1viruswillundergo
antigenic drift as it evolves and encounters immune pressure.
However, which mutations will arise, their location, and how the
mutationsmayaffectviralpathogenesisarenotknown.Forexam-
ple, a mutation at amino acid residue 222 of the HA protein has
been identiﬁed in virus isolates from some severely ill patients,
though its role in virulence is uncertain (15-19).
Here, we generate escape variants of the 2009 pH1N1 virus
with a human monoclonal antibody (hMAb; EM4C04) isolated
from a patient who became severely ill from 2009 pH1N1 virus
infection. This patient had a primary antibody response that was
highly speciﬁc for the 2009 pH1N1 virus (20). We identiﬁed the
binding epitope of the hMAb and found that the escape mutant
viruses displayed increased virulence in mice, associated with a
change in receptor speciﬁcity. Mapping hMAb epitopes is a nec-
essary step towards understanding antigenic drift in humans, and
our study identiﬁes the previously unappreciated potential for
antibody escape to enhance pathogenicity.
RESULTS
Generation of escape mutants against EM4C04. Peripheral
blood mononuclear cells (PBMCs) were collected from a hospi-
talized 30-year-old female patient infected with 2009 pH1N1 vi-
rus; her course was complicated by acute respiratory distress syn-
drome (ARDS), bacterial pneumonia, and pulmonary embolism
that required prolonged oscillatory ventilator support 31 days af-
ter admission (20). The EM4C04 antibody was isolated and puri-
ﬁedfromsortedIgGantibody-secretingcells(ASCs)aspreviously
described (20). This antibody speciﬁcally neutralized the 2009
pH1N1 virus, with no measured cross-reactivity with other inﬂu-
enzaviruses,includingseasonalH1N1inﬂuenzaviruses,whilethe
antibodies isolated from other patients were more broadly cross-
reactive (20). Therefore, it was of interest to map the binding
epitope of this unique antibody. To do so, escape mutant variants
were generated using the 2009 pH1N1 virus.
To map the epitope deﬁned by EM4C04, we sequenced 11 es-
capemutantsthatreplicatedinthepresenceofEM4C04(Table1).
The H3 numbering system was used to describe the amino acid
residues. Virus (EM18) was isolated from a control well in which
cells were inoculated with virus in the absence of EM4C04 anti-
body. The amino acid sequences of the HA gene of the parental
virus and the EM18 virus were identical, and both were used as
controls in subsequent assays.
A total of 7 different amino acid substitutions were identiﬁed
in the HAs of 11 mutant viruses (Table 1). No mutations were
identiﬁedintheNAgenesegment.TheD131Emutationappeared
in5oftheescapemutantviruses.Twoofthesubstitutions,K157N
and G158E, occurred in residues located in the Sa site of the HA
globularhead(10,21).Whilemutationsbetweenresidues153and
157 have been described following passage in cell culture (22), it
seems unlikely that this is the case for the K157N and G158E
mutations because no mutations were identiﬁed in the control
wells in which virus was incubated with the cells in the absence of
antibody. Also, each virus was ampliﬁed in MDCK cells, and no
mutations in this region or elsewhere arose due to cell culture
passage. Thus, we believe that the antigenic variants arose as a
result of antibody pressure from EM4C04.
Interestingly, the K123N and G134S substitutions create a po-
tential glycosylation site (23) deﬁned as an amino acid sequence
motif of Asn-Xaa-Ser/Thr, where Xaa can be any amino acid res-
idue except proline (23). A positive score from NetNGlyc at these
positionspredictedthatbothofthesesubstitutionswould,infact,
create N-linked glycosylation sites. A gel mobility shift assay
showedanincreaseinproteinsizeforHAexpressingtheK123Nor
G134S substitutions compared to the wild-type (wt) virus, sug-
gestingthattheHAwitheitherofthesemutationshadacquiredan
additional glycosylation site that likely blocks the binding epitope
ofEM4C04.AdditionofglycanstotheHAglobularheadhasbeen
shown to block neutralization of HA by monoclonal and poly-
clonal antibodies, as well as altering the receptor binding and fu-
sion properties of the HA (24). While the 2009 pH1N1 virus con-
tained only one glycosylation site on its globular head when it
emerged (25), it is likely to accumulate additional glycosylation
sites as it evolves.
Binding analysis of escape mutants. Enzyme-linked immu-
nosorbentassay(ELISA)bindingwasusedtodistinguishbetween
escapeduetoantigenicmutationsandthatduetoadsorptivemu-
tations(Fig.1).Antigenicmutationssigniﬁcantlyreduceantibody
bindingtothetargetepitope,whileadsorptivemutationsincrease
the binding afﬁnity of the virus to the host cell (9). Antigenic
mutantsshowsigniﬁcantlyloweropticaldensity(OD)valuesthan
do the wt parental viruses, demonstrating their inability to bind
the antibody, while adsorptive mutants show a binding pattern
TABLE 1 Summary of mutations generated in the presence of EM4C04
antibody
Mutant name Mutation(s)a
EM18 (parental virus) None
EM30 K123N
EM02 D131E
EM04 D131E
EM10 D131E
EM16 D131E
EM20 D131E
EM26 K133T
EM22 G134S
EM181 G134S
EM27 K157N, S186P
EM06 G158E
a Amino acid residues are identiﬁed using H3 numbering.
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antibodybindingisnotcompromisedinthesemutants.Figure1A
shows the results from an antibody binding ELISA, in which six
viruseswithmutationsatK123N,D131E,K133T,G134S,K157N/
S186P, and G158E, respectively, demonstrated signiﬁcantly re-
duced binding to EM4C04 compared to the CA/09 wt parental
virus(parentalvirus1)andtheEM18controlvirus(parentalvirus
2). Recombinant viruses expressing the K157N and S186P muta-
tions both individually and together were generated by reverse
genetics to determine the individual effect of each mutation on
EM4C04 binding. The K157N mutant showed signiﬁcantly re-
duced binding to EM4C04 in an antibody binding ELISA, while
the S186P mutant showed a binding pattern similar to that of the
parentalviruses(seeFig.S1inthesupplementalmaterial).Calcu-
lation of the dissociation constant (Kd) values for these recombi-
nant viruses, and the escape mutant viruses, listed in Fig. 1A,
showed that the S186P mutant had a higher binding afﬁnity for
EM4C04 than did the parental viruses, suggesting that S186P was
an adsorptive mutation (see Table S1 in the supplemental mate-
rial).ThiswasconﬁrmedbytreatingerythrocyteswithVibriochol-
erae neuraminidase receptor-destroying enzyme (RDE), which
removes terminal sialic acid (SA), the cellular ligand for HA. Ad-
sorptive mutants exhibit enhanced agglutination of RDE-treated
erythrocytes compared to the parental virus (9). In our study,
among the escape mutants, only the viruses expressing the S186P
mutation agglutinated RDE-treated erythrocytes better than did
thewtvirus,indicatingthatS186Pisanadsorptivemutation(data
not shown).
Hemagglutination inhibition (HAI) (Fig. 1B) and neutraliza-
tion (Fig. 1C) assays conﬁrmed the ELISA results. The six mutant
virusesexpressingtheK123N,D131E,K133T,G134S,K157N,and
G158E mutations also exhibited signiﬁcantly reduced neutraliza-
tion and HAI titers compared to the parental wt viruses. Recom-
binant viruses expressing the K157N and S186P mutations indi-
viduallyalsoshowedsigniﬁcantlyreducedHAIandneutralization
titers compared to the wt viruses. Adsorptive mutations decrease
HAI and neutralization antibody activities by increasing the viral
HA binding avidity for cell surface glycan receptors (9). The re-
FIG1 Bindinganalysisofescapemutants.(A)AbindingELISAwasperformedusingplatescoatedwitheachoftheindicatedvirusesintriplicate.Serialdilutions
of EM4C04 were added to the wells, followed by the addition of a secondary anti-human antibody conjugated to HRP. OD values were read at 450 nm. The
negative control was wells that had PBS alone added without virus. (B) Hemagglutination inhibition (HAI) assay comparing the HAI titers of CA/09 wt and
mutantviruses.TheHAItiterrepresentstheinverseofthehighestMAbdilutionatwhichhemagglutinationwasinhibited.(C)NeutralizationassayofCA/09wt
andmutantviruses.TheneutralizationtiterrepresentstheinverseofthehighestMAbdilutionatwhichaninfectivityof100TCID50oftheviruswasneutralized.
HAI and neutralization assays were performed in quadruplicate.
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inadditiontoitsenhancedagglutinationofRDE-treatederythro-
cytes, were not seen with the other mutant viruses and conﬁrm
that S186P is an adsorptive mutation.
When the mutations were mapped on the crystal structure of
the H1 HA, it appeared that the ﬁve residues (131, 133, 134, 157,
and 158) likely comprise the target epitope for the EM4C04 anti-
body(Fig.2).TheS186Pmutation,whichishighlightedinpurple,
was an adsorptive mutation that was not part of the EM4C04
binding site (Fig. 2). Amino acids 157 and 158 were previously
mapped to the H1N1 Sa antigenic site, suggesting that the
EM4C04 antibody binds to this antigenic site. Residues 131, 133,
and 134, contiguous with residues 157 and 158 in the globular
domain structure, have not been previously identiﬁed by epitope
mapping of escape mutants, suggesting that they contribute to a
novel pH1N1 antibody epitope site stretching from residues 157
to 134. Residue 123 is in close proximity to this epitope but is not
continuous with the other ﬁve residues. The glycosylation site
createdbytheK123Nsubstitutionlikelyinterfereswithbindingto
thisepitope.Itisalsopossiblethattheglycosylationsitecreatedby
theG134Smutationblocksthetargetepitopeinasimilarfashion.
Increased virulence of escape mutants in mice. Remarkably,
the D131E and S186P substitutions were recently shown to in-
crease virulence in mouse-passaged A/California/04/2009 (CA/4/
09) viruses compared to the parental virus (26, 27). In one study,
these two mutations alone were sufﬁcient to confer virulence in
mice (26). In our study, binding analysis identiﬁed D131E as an
antigenic mutation while S186P was adsorptive.
Therefore, we tested the in vitro replication and virulence of
mutants expressing either the D131E mutation (EM02) or the
S186Pmutation(EM27)inmice,relativetotheparentalCA/09wt
virus. The escape mutant viruses generated by passage of the pa-
rentalCA/09wtvirusinthepresenceofEM4C04arereferredtoas
“biological viruses.” The recombinant K157N and S186P viruses
were used in order to distinguish the individual effects of each
mutationoninﬂuenzavirusvirulence.Inaddition,wegenerateda
recombinant CA/09 wt virus and recombinant viruses expressing
the D131E mutation alone and the D131E and S186P mutations
together. The binding analyses used to characterize the escape
mutants, such as ELISA, HAI, neutralization, and RDE avidity
assays, were performed with the recombinant mutants to deter-
mine whether they behaved similarly to their biological counter-
parts.
Initially, the biological and recombinant viruses were com-
pared to the wt viruses in vitro in MDCK cells inoculated at a
multiplicity of infection (MOI) of 0.1 (see Fig. S2 in the supple-
mental material). Virus titers peaked at about 24 h postinfection.
TheK157N/S186Precombinant,S186Precombinant,andD131E
recombinant viruses showed higher titers than did the CA/09 wt
virus at 24 h postinfection, and the K157N/S186P and D131E
recombinant viruses maintained a 10-fold-higher titer than did
the CA/09 wt virus at 48 and 72 h postinfection, suggesting that
FIG 2 Map of EM4C04 escape mutations on the HA surface. (A and C) Diagram of the 2009 pH1N1 HA protein with both a side view (A) and a top view (C).
(A) The locations of the amino acid residues identiﬁed as escape mutations that allow escape from EM4C04 neutralization are highlighted in red (residues 131,
133,134,157,and158),blue(123),andpurple(186).(B)Azoomed-inviewofthelocationsoftheﬁveaminoacidresiduesthatlikelycomprisetheEM4C04target
epitope is shown with the residues labeled. A sialic acid molecule is shown (highlighted in green) to indicate the location of the receptor binding site of the HA
protein.
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CA/09wtvirus.Overall,thedatasuggestthatthereareonlyminor
differencesinviralﬁtnessinvitrobetweentheCA/09wtandmost
of the mutant viruses.
Tocomparethevirulenceofthemutantvirusesandthatofthe
wt viruses in vivo, we ﬁrst evaluated the response to a dose of 105
50%tissuecultureinfectiousdoses(TCID50)ofeachvirusinmice.
Consistent with previous results, the biological and recombinant
CA/09wtvirusescaused15%weightlossbutwerenotlethalfor
BALB/c mice (100% survival) (Fig. 3A and 3B) (26). In contrast,
the biological and recombinant viruses expressing either the
D131E or S186P mutation or both mutations were lethal at this
dose (Fig. 3A and 3B), with mice dying between 5 and 7 days
postinfection (dpi) (Fig. 3B); 20% to 40% of the mice infected
withtheD131EandS186Pmutantviruseswerefounddead,while
the rest were euthanized after a 25% loss in body weight. None
of the mice infected with viruses expressing the D131E mutation
survived, and only 20% of the mice infected with the S186P re-
combinantvirussurvived.TherecombinantK157Nviruswasnot
lethal (100% survival) and produced a pattern of weight loss sim-
ilar to that of the parental viruses (Fig. 3A and 3B), implicating
S186P in the lethality of the double mutant K157N/S186P virus.
The remaining escape variants (K123N, K133T, G134S, and
G158E) were not lethal for mice at a dose of 105 TCID50, with
100% of the mice surviving. Thus, the D131E and S186P muta-
tions speciﬁcally alter the virulence of the 2009 pH1N1 virus in
mice (see Fig. S3 in the supplemental material).
We next determined the 50% mouse lethal dose (MLD50) for
the wt virus and escape mutants (Table 2). Lethality was observed
only at very high doses of the CA/09 wt virus. The D131E substi-
FIG3 WeightlossandlethalityinmiceinfectedwiththeD131EandS186PCA/09mutants.Weightloss(A)andmortality(B)weremonitoredfor14daysafter
intranasal inoculation with 105 TCID50 of biological and recombinant CA/09 wt and mutant viruses in groups of ﬁve mice. Mice were euthanized if they lost at
least25%oftheiroriginalbodyweight.InpanelA,thenumbersbesideeachlinerepresentthenumberofmicethatsurvivedpergroupofﬁvemice.Numbersin
parentheses represent results from multiple groups.
TABLE 2 Virulence of CA/09 wt and mutant viruses in mice
Virus MLD50 (log10 TCID50)
CA/09 wt biological 5.8
CA/09 wt recombinant 5.5a
D131E recombinant 4.2
D131E biological 3.8
K157N/S186P recombinant 4.4
K157N/S186P biological 3.6
D131E/S186P recombinant 3.2
a CA/09 wt recombinant virus MLD50 was determined in a separate experiment.
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and S186P mutations decreased the MLD50 by 100-fold (Ta-
ble 2). Because we sequenced only the HA and NA genes of the
escapemutantviruses,wecannotexcludethepossibilitythatmu-
tations in other viral genes of the biologically derived mutant vi-
ruses that affect the pathogenicity phenotype may be present.
The effect of the mutations on viral replication in the respira-
torytractofmicewasassessedbymeasuringtitersinthelungsand
nasal turbinates at days 2 and 4 postinfection (see Fig. S4 in the
supplemental material). Mice infected with the K157N mutant
virus displayed lung virus titers similar to those of the wt viruses
(see Fig. S4A and S4B). Modestly higher (~2.5- to 6-fold) titers
wereobservedonbothdaysinmiceinfectedwithvirusesexpress-
ing the D131E or S186P mutation than in those infected with the
wtviruses(seeFig.S4AandS4B).Miceinfectedwithrecombinant
D131E/S186P virus showed signiﬁcantly higher viral titers in the
lungsonbothdaysthandidthewtviruses(~13-to27-foldatdays
2 and 4, respectively) and viruses expressing only a single muta-
tion (see Fig. S4A and S4B). Overall, the differences were modest,
andalthoughtheyachievedstatisticalsigniﬁcance,theirbiological
signiﬁcance is questionable.
In the nasal turbinates, as in the lungs, mice infected with the
K157Nmutantshowedtiterssimilartothoseofthewtviruses(see
Fig. S4C and S4D in the supplemental material). However, mice
infected with viruses expressing the D131E or S186P mutation
showed signiﬁcantly higher titers in the upper respiratory tract
onlyatday4comparedtothewtviruses,withabouta5-to10-fold
increase in titer (see Fig. S4D). The D131E/S186P recombinant
mutantvirusachievedsigniﬁcantlyhighertitersonbothdaysthan
didthewtviruses,witha6-to10-fold-highertiterondays2and4,
respectively(seeFig.S4CandS4D).However,asigniﬁcantdiffer-
ence in titer was not seen between the D131E/S186P mutant and
viruses expressing the individual mutations (see Fig. S4C and
S4D).
SA receptor speciﬁcity. HA binds to sialic acid (SA) linked to
oligosaccharidesidechainswith(2,3)-Galor(2,6)-Galresidues
(28). The HA from human isolates typically preferentially binds
(2,6)-Gal-linkedSA,whileavianHAspreferentiallybind(2,3)-
Gal-linked SA (29, 30). In the lower respiratory tract of mice,
(2,3)-Gal-linked SA predominates over (2,6)-Gal-linked SA
(31, 32). Mouse-adapted human inﬂuenza viruses with increased
virulence can display a change in receptor speciﬁcity with en-
hanced binding to (2,3)-Gal-linked SA (9, 33). Therefore, we
tested the receptor speciﬁcity of the D131E and S186P mutant
viruses in an assay using de-/resialylated chicken red blood cells
(cRBCs) (Table 3). Chicken erythrocytes typically express both
(2,3)- and (2,6)-Gal-linked SA but can be desialylated and re-
sialylated to express only (2,3)- or (2,6)-Gal-linked SA. The
CA/09wtvirusesbound(2,6)-Gal-linkedSAbutnot(2,3)-Gal-
linkedSAcRBCs.Incontrast,mutantvirusesexpressingeitherthe
D131E or S186P mutation bound (2,6)-Gal-linked SA and
showed some binding to (2,3)-Gal-linked SA cRBCs. These re-
sults were conﬁrmed in hemagglutination assays using turkey
erythrocytes that express both (2,3)- and (2,6)-Gal-linked SA
and horse red blood cells (hRBCs) that express only (2,3)-Gal-
linked SA (Table 3). Thus, the CA/09 wt viruses failed to bind
horse red blood cells while viruses expressing either the D131E or
S186P mutation showed some binding to these cells (Table 3).
Together, these results demonstrate that the D131E and S186P
mutations modulate receptor binding speciﬁcity, resulting in a
virus that is able to bind both (2,3)-Gal-linked SA and (2,6)-
Gal-linked SA.
DISCUSSION
The purpose of this study was to map the epitope of an hMAb
generated in response to a primary infection with 2009 pH1N1
virus to broaden our understanding of antigenic drift with the
2009 pH1N1 virus. We postulated that under immune pressure
with the hMAb EM4C04, the 2009 pH1N1 virus would undergo
antigenic drift and mutate at sites that would identify the binding
site of the antibody. The binding site was identiﬁed and mapped
by generating escape mutant viruses. Surprisingly, we found that
some of the escape mutants displayed increased virulence in mice
thatwaslikelytheresultofalteredreceptorspeciﬁcitythatallowed
the viruses to bind both (2,3)-Gal-linked SA and (2,6)-Gal-
linked SA.
Although the in vitro generation of escape mutants is unlikely
torecapitulatedriftinitsentirety,thisislargelyduetothestochas-
tic nature of drift and the very large mutational space available.
However, mapping hMAb epitopes is a necessary step towards
TABLE 3 Comparison of sialic acid binding speciﬁcities
Virus
HA titer with indicated RBCs
De-/resialylation assay
tRBCs hRBCs SA2,3 resialylated cRBCs SA2,6 resialylated cRBCs Desialylated cRBCs Untreated cRBCs
CA/09 wt biological 1a 128 1 128 64b 1
CA/09 wt recombinant 1 128 1 128 64 1
D131E biological 4 128 1 128 64 4
D131E recombinant 4 128 1 128 64 4
K157N/S186P biological 8 128 1 128 64 4
K157N/S186P recombinant 4 128 1 128 64 8
S186P recombinant 8 128 1 128 64 8
D131E/S186P recombinant 8 128 1 128 64 4
H2 SA2,6 controlc 1 128 1 128 64 1
H2 SA2,3 control 128 1 1 128 64 64
a For assay with cRBCs, HA titers ranged from 1 to 128.
b For assay with tRBCs and hRBCs, viruses were standardized to an HA titer of 64.
c Controls were recombinant A/Japan/57 (H2N2) viruses with either the 226L/228S amino acid combination (H2 SA2,6 control) or the 226Q/228G amino acid combination (H2
SA2,3 control).
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the previously unappreciated potential for antibody escape to en-
hancepathogenicity.Ournovelﬁndingoftheemergenceofescape
variantswithincreasedpathogenicitymakesusrethinkpathogen-
esis, as we directly show that antibody escape can inadvertently
increase pathogenesis. While the D131E and S186P mutations
speciﬁcally identiﬁed in this study may not necessarily increase
virulence in humans, our study deﬁnitively establishes the poten-
tial for this to occur.
Additionally, we deﬁned the speciﬁcity of an hMAb that spe-
ciﬁcally targeted the 2009 pH1N1 virus, deﬁning a novel epitope
withresiduespreviouslybelievedtobenonantigenic.Wemapped
the EM4C04 binding site to a novel epitope that includes residues
from the Sa antigenic site of the HA protein. Other hMAbs have
been mapped to nearby epitopes on the globular head of the HA
close to the receptor binding pocket, including a study that iden-
tiﬁed escape mutants at amino acid residue 133 on the pH1N1
virus(34,35).ItisdifﬁculttojudgetowhatextenthMAbEM4C04
is representative, especially considering that the majority of anti-
bodies induced after infection with pandemic H1N1 viruses were
cross-reactive. However, while cross-reactive Abs may predomi-
nate in adults with many prior infections/vaccination, it is likely
that more strain-speciﬁc Abs predominate in children, particu-
larly after their ﬁrst infection. This population may be largely re-
sponsible for antigenic drift. The EM4C04 antibody was isolated
from a severely ill 30-year-old female patient with complications
of ARDS, bacterial pneumonia, and pulmonary embolism (20).
Her antibody response was concluded to be characteristic of a
primary antibody response, presumably due to lack of previous
exposuretorelatedinﬂuenzaviruses,basedonthehighspeciﬁcity
against 2009 pH1N1, the low levels of somatic mutation in the
variablegenesfromtheplasmablasts,andtheseverediseaseinthe
absenceofpredisposingconditions(20).Atleasttwootherstudies
have shown that antibodies generated following pH1N1 infection
targettheSaregion,asdoesEM4C04(36,37).Takentogether,the
studies suggest that the Sa region is an immunodominant anti-
genic site on the 2009 pH1N1 virus, which may drift as the 2009
pH1N1 virus evolves (36, 37).
Escape mutant variants expressing the D131E or S186P muta-
tion exhibited increased virulence in mice compared to the wt
parental virus, suggesting that these two residues are virulence
determinants for the 2009 pH1N1 virus. These viruses caused
greater morbidity in mice, showed increased viral replication in
the lower respiratory tract, and were lethal at lower doses. Either
mutation alone was sufﬁcient to confer increased virulence, with
the expression of both mutations resulting in a minor enhance-
ment in virulence. To our knowledge, this is the ﬁrst study to use
anhMAbtogenerate2009pH1N1escapemutantvariantsinvitro.
Previousstudieshaveidentiﬁedvirulentvirusesexpressingsimilar
mutationsfollowinganalternativeselectionmethodofserialpas-
sage in mice in the absence of preexisting immune responses (26,
27). Mutations generated using hMAbs, however, are likely to
more accurately predict mutations that could arise as inﬂuenza
viruses circulate in humans. The generation of more-virulent vi-
ruses expressing the D131E and S186P mutations extends results
from passage in mice using the closely related A/California/04/
2009 pH1N1 virus and argues that these residues are virulence
determinants that may emerge in humans as a result of antigenic
drift. However, the scenario in natural infection associated with a
polyclonal antibody response is undoubtedly more complex than
selection pressure placed on a virus by a single monoclonal anti-
body. Thus, the implications of our ﬁndings cannot be directly
extrapolated to humans.
The enhanced virulence of the mutant viruses is probably re-
lated to a change in SA receptor speciﬁcity. While CA/09 wt vi-
ruses speciﬁcally bind to only (2,6)-Gal-linked SA, viruses ex-
pressingeithertheD131EorS186Pmutationboundboth(2,6)-
Gal-linked SA and (2,3)-Gal-linked SA. The close proximity of
theseresiduestothereceptorbindingsite(RBS)likelycontributes
to their ability to alter SA binding. The predominance of (2,3)-
Gal-linked SA in the lower respiratory tract of mice (31, 32) and
thefactthatmouse-adaptedhumaninﬂuenzaviruses,whichshow
increased virulence compared to the parental viruses, can display
enhancedbindingto(2,3)-Gal-linkedSA(9,33)suggestthatthe
D131E and S186P mutants display increased viral replication in
the lungs and enhanced virulence in mice because of their ability
tobind(2,3)-Gal-linkedSA.Interestingly,theD222Gmutation,
which may be associated with increased virulence in the 2009
pH1N1 virus in humans (15-19), also alters receptor speciﬁcity
(38, 39). Notably, while the D131E and S186P mutations were
found to increase binding afﬁnity for (2,3)-Gal-linked SA, the
viruses did not lose their ability to bind (2,6)-Gal-linked SA.
Together, these results suggest that the acquired ability to bind
both (2,3)- and (2,6)-Gal-linked SA may be associated with
increased virulence for the 2009 pH1N1 virus.
While others have speculated as to why these mutations result
in increased virulence (26), our study suggests that it results from
altered receptor speciﬁcity. In humans, (2,6)-Gal-linked SA is
predominantly found in the upper respiratory tract while (2,3)-
Gal-linked SA is predominantly present in the lower respiratory
tract(40-42).Humaninﬂuenzavirusesaregenerallycharacterized
by their binding preference for (2,6)-Gal-linked SA, while avian
inﬂuenza viruses preferentially bind (2,3)-Gal-linked SA (40-
42), though the virus-host interactions that lead to disease patho-
genesis in intact animals and humans are likely to be much more
complexthanthereceptorbindingpreferenceparadigmsuggests.
The131Eand186Pmutationshavepreviouslybeencharacterized
as avian-type mutations because of their presence in the 1918
H1N1 viruses of avian origin (26). Thus, it is not surprising that
wefoundthatmutantvirusesexpressingtheD131EorS186Pmu-
tationacquiredtheabilitytobind(2,3)-Gal-linkedSA.Thisnew
phenotype could have signiﬁcant consequences if the viruses are
able to replicate more efﬁciently in the human lower respiratory
tract. Highly pathogenic avian inﬂuenza (HPAI) H5N1 viruses,
which preferentially bind (2,3)-Gal-linked SA, are associated
with a case fatality rate of ~60% in laboratory-conﬁrmed cases
that meet the World Health Organization deﬁnition (43, 44).
However, the actual case fatality rate may be signiﬁcantly lower
(45,46).TheseverediseasecausedbyHPAIH5N1isbelievedtobe
at least in part due to preferential infection of the human lower
respiratory tract (41, 42, 47, 48). This emphasizes the role of in-
ﬂuenza virus infection of the human lower respiratory tract as a
key event in the pathogenesis of severe disease and/or death. Ye et
al. (26) examined the transmissibility of viruses expressing the
D131EandS186Pmutationsinferrets,whichhaveanSAreceptor
distributionsimilartothatofhumans,andconcludedthatviruses
expressing these mutations are transmitted to levels similar to
those of the parental viruses, suggesting that these mutations do
not negatively affect viral growth or transmissibility (26).
A comparison of 4,200 published 2009 pH1N1 HA sequences
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and 186P residues are infrequent among currently circulating
2009 pH1N1 viruses. Only 12 (0.29%) isolates expressed 131E,
while13(0.30%)expressed186P.Insomeinstances,amixedpop-
ulation of sequences with 131D or 186S was present, suggesting
that the variants may exist as a minor quasispecies that could be
selected under immune pressure. However, the number of 2009
pH1N1 human isolates expressing the S186P mutation has in-
creased from 2009 to 2011, and it is possible that this trend may
continue. Information was not available regarding the severity of
disease in patients from whom these viruses were isolated. Our
data show that there is the potential for escape mutants that arise
as a result of antigenic drift to be more virulent than the parental
virus in mice.
The 131E and 186P residues are common among classical
swine inﬂuenza viruses. For instance, the 131E residue was iden-
tiﬁed in viruses such as A/swine/Iowa/1930 and A/New Jersey/8/
1976, while the 186P residue was identiﬁed in A/Alaska/1935 and
A/New Jersey/8/1976. Both residues were also conserved in the
1918 H1N1 inﬂuenza viruses, which caused a pandemic that was
responsible for as many as 50 million deaths worldwide (49). If
expression of the 131E and 186P residues in the 1918 inﬂuenza
virus contributed to its highly virulent phenotype, then the emer-
genceoftheseresiduesinthe2009pH1N1virusandtheireffecton
virulenceshouldbecloselymonitored.Interestingly,the186Pres-
idue is also conserved among most seasonal H1N1 inﬂuenza vi-
rusesisolatedfrom1998to2007.Ifthe186Presiduedoescontrib-
ute to increased virulence, it seems likely that additional genomic
changes decrease the pathogenic potential of 186P in seasonal
H1N1 inﬂuenza viruses. And while it is possible that the 186P
residue does not have an effect on virulence in humans, the in-
crease in 2009 pH1N1 isolates expressing the S186P mutation
from2009to2011stillsuggeststhatthismutationisbeingselected
for in humans.
Our analysis of available sequences shows that 2009 pH1N1
viruses have acquired mutations at all 13 residues previously
mapped to the Sa antigenic site while changes in the other anti-
genic sites have been much more limited. This supports the con-
clusion that the Sa antigenic site is the immunodominant anti-
genic site (36, 37). However, it is not known if these mutations
arose as a result of pressure from EM4C04-like antibodies in vivo.
For the mutations speciﬁcally identiﬁed in this study, the 133T,
134S, and 157N mutations were not reported in H1N1 isolates
priorto2009,suggestingthattheseresiduesarespeciﬁcfeaturesof
the 2009 pH1N1 HA. The 158E residue is present in some H1N1
viruses isolated in the early 1930s, including A/PR/8/34 and
A/swine/Iowa/30. The G158E mutation was detected as a quasi-
species in viral RNA extracted from the lung tissue of a 2009
pH1N1 virus-infected patient who died of viral pneumonia (50).
The K123N and G134S mutations likely generate glycosylation
sitesontheHAglobularhead.TheK123Nmutationwasalsoseen
in a 2009 pH1N1 mouse-adapted virus (27). In the past, there has
been a tendency towards the accumulation of glycosylation sites
on the globular head of the HA as pandemic inﬂuenza viruses
evolve in humans (23, 25). The functional importance of these
sites lies in their ability to mask antigenic regions and prevent
neutralization by antibodies (25). Detection of the K123N and
G134S substitutions in our study has identiﬁed the positions of
two potential glycosylation sites that may emerge as a result of
antigenic drift as the 2009 pH1N1 virus circulates in humans.
Inconclusion,wehaveshownthat2009pH1N1escapemutant
viruses generated in vitro under immunological pressure with an
hMAbspeciﬁcforanovelepitopeintheSaantigenicsiteoftheHA
protein can inadvertently lead to the generation of viruses with
altered receptor speciﬁcity and enhanced virulence. These novel
ﬁndings broaden our understanding of inﬂuenza antigenic drift
anditspossibleconsequencesonpathogenicity.Theemergenceof
mutationsinthe2009pH1N1virusandtheireffectonviralpatho-
genicity should be closely monitored.
MATERIALS AND METHODS
Viruses. The wild-type (wt) 2009 pH1N1 virus, A/California/07/2009
(CA/09), was kindly provided by Ruben Donis and Alexander Klimov
fromtheInﬂuenzaDivision,CentersforDiseaseControlandPrevention,
Atlanta, GA. Recombinant CA/09 viruses were generated by reverse ge-
neticsasdescribedpreviously(51).Inaccordancewiththemanufacturer’s
protocol, site-directed mutagenesis (Agilent Technologies) was used to
introduce mutations into HA to create CA/09 recombinant viruses for in
vivo studies. The wt and recombinant viruses were propagated in the
allantoic cavity of 9- to 11-day-old embryonated speciﬁc-pathogen-free
hen’s eggs. Eggs inoculated with the viruses were incubated at 35°C, and
allantoic ﬂuid was harvested 48 to 72 h later, tested for hemagglutinating
activity, and stored at 80°C until use. The 50% tissue culture infectious
dose(TCID50)foreachviruswasdeterminedbyserialtitrationofvirusin
MDCK cells and calculated by the method developed by Reed and
Muench (52). For the receptor speciﬁcity assays, inﬂuenza viruses with
known binding preferences for either SA2,3 or SA2,6 were used as
controls.
Antibody. The generation of the human monoclonal antibody
EM4C04 was described by Wrammert et al. (20). This antibody was pu-
riﬁedfromIgGantibody-secretingcells(ASCs)fromtheperipheralblood
mononuclear cells (PBMCs) of a patient infected with the 2009 pH1N1
virus as described elsewhere (20).
Animals. Six- to 8-week-old female BALB/c mice (Taconic Farms,
Inc.,Germantown,NY)wereusedtoevaluatethelethalityandreplication
of the wt and mutant CA/09 viruses. Postinfection polyclonal serum
against the CA/09 wt virus was generated in 6-month-old female BALB/c
mice. The National Institutes of Health Animal Care and Use Committee
approved all animal experiments.
Generation of escape mutants. CA/09 wt virus was serially diluted
2-foldinminimumessentialmedium(MEM)inround-bottomed96-well
plates. EM4C04 antibody with an original concentration of 600 g/milli-
liter was diluted 1:1,000 and added to the virus. The virus-antibody mix-
ture was incubated for 30 min at room temperature and then transferred
toMDCKcellsculturedin96-wellplates.Thevirus-antibodymixturewas
incubated with the cells for2ha t37°C, after which the mixture was
removed, and fresh MEM [supplemented with 4 mM L-glutamine, 1
antibiotic-antimycotic (Gibco Ant-Anti, Invitrogen), and 1 g/milliliter
L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)] containing
EM4C04(diluted1:10,000)wasadded.Controlcellswereinoculatedwith
virus alone in the absence of EM4C04. Cells were incubated at 37°C for
4 days and checked for the presence of cytopathic effect (CPE). The anti-
body dilutions used provided concentrations of EM4C04 that were opti-
mal for driving the emergence of escape mutants for this particular anti-
body.
Sequencingofescapemutants.ViralRNAwaspuriﬁedfromaliquots
of supernatant taken from wells showing evidence of CPE using the QI-
Amp viral RNA minikit (Qiagen). To generate cDNA, reverse transcrip-
tasePCR(RT-PCR)wasperformed,accordingtothemanufacturer’spro-
tocol, using the Qiagen One Step RT-PCR kit. The HA and NA gene
segments were ampliﬁed and PCR products were puriﬁed using the
QIAquick PCR puriﬁcation kit. DNA sequencing was performed on an
Applied Biosystems 3730 DNA analyzer.
Monoclonal antibody binding analysis. As previously described (9),
wt and mutant CA/09 viruses diluted in phosphate-buffered saline (PBS)
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cubation at 4°C for at least 16 h, wells were blocked with PBS-5% fetal
bovine serum (FBS) for1ha troom temperature. A nonsaturating con-
centrationofthehumanEM4C04antibody(diluted1:1,000)inthelinear
portion of the antibody titration curve determined previously was added
to each well, serially diluted 2-fold, and incubated with the virus-coated
plates for1ha troom temperature. After washing, anti-human horserad-
ish peroxidase (HRP)-conjugated antibody was added to the plates, and
they were incubated for1ha troom temperature. After another round of
washing, TMB (3,3=,5,5=-tetramethylbenzidine) substrate (KPL Biomed-
ical) was added, and HCl was used to stop the reaction. The amount of
HRP product was determined using a plate reader at 450 nm. Antibody
bindingtotheM2proteinwasalsomeasuredtoverifythattheplateswere
coated with similar amounts of virus. Based on these antibody titrations,
dissociation constants (Kds) were calculated using GraphPad Prism.
HAI assay. As previously described (53), HAI assays were performed
in 96-well V-bottomed plates. The EM4C04 antibody was 2-fold serially
dilutedstartingatadilutionof1:10,and4hemagglutinatingunitsofvirus
was added. Control wells received PBS alone or PBS with virus in the
absence of antibody. Virus and EM4C04 antibody were incubated to-
gether for 30 min at room temperature. Next, 50 l of a 0.5% (vol/vol)
turkey erythrocyte solution was added. The antibody, virus, and erythro-
cytesweregentlymixed,andtheresultswererecordedafterincubationfor
45to60minatroomtemperature.HAItiterswererecordedastheinverse
of the highest antibody dilution that inhibited the agglutination of red
blood cells.
In vitro neutralization assay. As previously described (54), wt and
mutant viruses were diluted to a concentration of 100 TCID50 per 50 l
(103.3 TCID50/ml) in MEM-0.5% bovine serum albumin (BSA). Serial
dilutionsoftheEM4C04antibodyormouseseraweremixedwitheachof
the viruses and incubated at room temperature for 1 h. After 1 h, the
virus-antibody mixture was added in quadruplicate to MDCK cells cul-
turedin96-wellplates.Cellswereincubatedat37°C,andvirusgrowthwas
scored 4 days later by CPE. The neutralization titer is the inverse of the
highest EM4C04 dilution where infectivity was neutralized.
Assessment of lethality in mice. We administered 50 l containing
105 TCID50 of the biological and recombinant CA/09 wt and mutant
viruses intranasally (i.n.) to groups of 5 lightly anesthetized 6- to 8-week-
oldfemaleBALB/cmice.Bodyweightswererecordeddailyforaperiodof
14 days following infection. Mice that lost 25% of their initial body
weight were sacriﬁced according to the institutional animal care and use
committee guidelines.
To determine the 50% mouse lethal doses (MLD50s) of selected vi-
ruses, groups of ﬁve 6- to 8-week-old female BALB/c mice were lightly
anesthetizedandinfectedwith50lof10-foldserialdilutionscontaining
101 to 106 TCID50 of the viruses. Mice were monitored daily for 14 days
postinfection (dpi) for changes in body weight and mortality.
RDEavidityassay.Aspreviouslydescribed(9),a10%(vol/vol)turkey
erythrocyte solution was treated with various concentrations (1 U,
500mU,50mU,25mU,10mU,5mU,and0U)ofV.choleraeneuramin-
idase receptor-destroying enzyme (RDE) for1ha t37°C. The cells were
washed,dilutedto2%(vol/vol)inPBS,andaddedto96-wellV-bottomed
plates containing 4 HA units of the biological and recombinant viruses.
The plates were gently shaken, and the results were recorded after incu-
bation for 45 to 60 min at room temperature.
Assessment of viral replication in mice. To assess the ability of the
biological and recombinant CA/09 wt and mutant viruses to replicate in
the respiratory tract, groups of 8 lightly anesthetized female BALB/c mice
wereinoculatedwith50lcontaining105TCID50ofthedifferentviruses.
On days 2 and 4 postinfection, the lungs and nasal turbinates were har-
vested.OrganswereweighedandhomogenizedinL-15mediumcontain-
ing antibiotic-antimycotic (Invitrogen-Gibco) to make 10% (wt/vol) tis-
sue homogenates. Tissue homogenates were clariﬁed by low-speed
centrifugation and titrated in 24- and 96-well culture plates containing
MDCK cells. Titers are expressed as log10 TCID50/g of tissue.
Hemagglutination assay. CA/09 wt and mutant viruses standardized
to an HA titer of 64 were 2-fold serially diluted in PBS in 96-well
V-bottomedplates.Next,50lofa0.5%(vol/vol)erythrocytesolutionof
eitherturkeyredbloodcells(tRBCs)orhorseredbloodcells(hRBCs)was
added.Thevirusanderythrocytesweregentlymixed,andtheresultswere
recorded after incubation for 30 to 60 min at room temperature.
De-/resialylation assay. Chicken red blood cells (cRBCs) (10%)
(HEMA Resource and Supply Inc.) were desialylated by incubation with
250 mU/l Clostridium perfringens neuraminidase (Sigma) for 1 h at
37°C. The cells were then washed twice in PBS and resuspended in
PBS-1% BSA. The cells were resialylated by incubating aliquots of cRBCs
withCMP-sialicacid(Sigma)andeither2,3-sialyltransferase(Sigma)or
2,6-sialyltransferase (Calbiochem) for 1.5 h at 37°C. The resialylated
cRBCs were then washed 3 times in PBS and resuspended in PBS at a 1%
concentration, and a hemagglutination assay was performed as described
above.H2N2Japan/57(JP/57)recombinantviruseswithknownreceptor
speciﬁcities were used as controls. H2N2 JP/57 L-S with the 226L/228S
aminoacidcombinationpreferentiallybinds2,6-sialicacid,whileH2N2
JP/57 Q-G with the 226Q/228G amino acid combination speciﬁcally
binds 2,3-sialic acid. Each virus was also tested against untreated cRBCs
and desialylated cRBCs.
In vitro viral replication kinetics. MDCK cells cultured in 24-well
plates were inoculated in triplicate with CA/09 wt and mutant viruses for
1hat37°CatanMOIof0.1.Thesupernatantwascollected0,8,24,36,48,
and 72 h later and stored at 80°C until the samples were titrated on
MDCK cells.
Statistical analysis. The signiﬁcance of difference between any two
different groups was assessed by a nonparametric Mann-Whitney test
using Prism (GraphPad Software). P values of 0.05 are considered sig-
niﬁcantly different.
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